Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals.

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO; SPARTAC Trial Investigators, Kellam P, Pybus OG.

Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676). pii: 20140241. doi: 10.1098/rstb.2014.0241.

2.

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators.

PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.

3.

HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.

Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, Babiker A, Weber J, Porter K, Phillips RE; SPARTAC Trial Investigators.

AIDS. 2014 Mar 13;28(5):699-708. doi: 10.1097/QAD.0000000000000130.

PMID:
24549145
4.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
5.

Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.

Gall A, Kaye S, Hué S, Bonsall D, Rance R, Baillie GJ, Fidler SJ, Weber JN, McClure MO, Kellam P; SPARTAC Trial Investigators.

Retrovirology. 2013 Jan 18;10:8. doi: 10.1186/1742-4690-10-8.

6.

Short-course antiretroviral therapy in primary HIV infection.

SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A.

N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039.

7.

Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.

Yager N, Robinson N, Brown H, Flanagan P, Frater J, Fidler S, Weber J, Phillips R; SPARTAC Trial Investigators.

AIDS. 2013 Jan 28;27(3):313-23. doi: 10.1097/QAD.0b013e32835b8cf5.

PMID:
23095315
8.

Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.

English S, Katzourakis A, Bonsall D, Flanagan P, Duda A, Fidler S, Weber J, McClure M; SPARTAC Trial Investigators, Phillips R, Frater J.

Retrovirology. 2011 Jul 7;8:54. doi: 10.1186/1742-4690-8-54.

9.

Modelling the evolution and spread of HIV immune escape mutants.

Fryer HR, Frater J, Duda A, Roberts MG; SPARTAC Trial Investigators, Phillips RE, McLean AR.

PLoS Pathog. 2010 Nov 18;6(11):e1001196. doi: 10.1371/journal.ppat.1001196.

10.

HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection.

Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M, McClure M, McLean AR, Fidler S, Weber J, Phillips RE, Frater AJ; SPARTAC Trial Investigators.

J Virol. 2009 Feb;83(3):1228-39. doi: 10.1128/JVI.01545-08. Epub 2008 Nov 19.

Supplemental Content

Loading ...
Support Center